121 related articles for article (PubMed ID: 38253218)
1. METTL3-mediated HSPA9 m6A modification promotes malignant transformation and inhibits cellular senescence by regulating exosomal mortalin protein in cervical cancer.
Ao K; Yin M; Lyu X; Xiao Y; Chen X; Zhong S; Wen X; Yuan J; Ye M; Zhang J; Li X; Hao Y; Guo X
Cancer Lett; 2024 Apr; 587():216658. PubMed ID: 38253218
[TBL] [Abstract][Full Text] [Related]
2. Restoration of p53 functions by suppression of mortalin-p53 sequestration: an emerging target in cancer therapy.
Shankaranarayana AH; Meduri B; Pujar GV; Hariharapura RC; Sethu AK; Singh M; Bidye D
Future Med Chem; 2023 Nov; 15(22):2087-2112. PubMed ID: 37877348
[TBL] [Abstract][Full Text] [Related]
3. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
[TBL] [Abstract][Full Text] [Related]
4. Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in
Wu PK; Hong SK; Park JI
Mol Cell Biol; 2017 Sep; 37(18):. PubMed ID: 28674184
[TBL] [Abstract][Full Text] [Related]
5. METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA.
Du QY; Huo FC; Du WQ; Sun XL; Jiang X; Zhang LS; Pei DS
Oncogene; 2022 Sep; 41(39):4420-4432. PubMed ID: 35987795
[TBL] [Abstract][Full Text] [Related]
6. Mortalin (HSPA9) facilitates
Wu PK; Hong SK; Chen W; Becker AE; Gundry RL; Lin CW; Shao H; Gestwicki JE; Park JI
Sci Signal; 2020 Mar; 13(622):. PubMed ID: 32156782
[TBL] [Abstract][Full Text] [Related]
7. Methyltransferase-like 3 promotes cervical cancer metastasis by enhancing cathepsin L mRNA stability in an N6-methyladenosine-dependent manner.
Liu P; Ju M; Zheng X; Jiang Y; Yu X; Pan B; Luo R; Jia W; Zheng M
Cancer Sci; 2023 Mar; 114(3):837-854. PubMed ID: 36382580
[TBL] [Abstract][Full Text] [Related]
8. Mortalin - a multipotent chaperone regulating cellular processes ranging from viral infection to neurodegeneration.
Flachbartová Z; Kovacech B
Acta Virol; 2013; 57(1):3-15. PubMed ID: 23530819
[TBL] [Abstract][Full Text] [Related]
9. METTL3 promotes glycolysis and cholangiocarcinoma progression by mediating the m6A modification of AKR1B10.
Cai J; Cui Z; Zhou J; Zhang B; Lu R; Ding Y; Hu H
Cancer Cell Int; 2022 Dec; 22(1):385. PubMed ID: 36476503
[TBL] [Abstract][Full Text] [Related]
10. METTL3-mediated m6A modification of SIRT1 mRNA inhibits progression of endometriosis by cellular senescence enhancing.
Wang X; Wang J; Zhao X; Wu H; Li J; Cheng Y; Guo Q; Cao X; Liang T; Sun L; Zhang G
J Transl Med; 2023 Jun; 21(1):407. PubMed ID: 37353804
[TBL] [Abstract][Full Text] [Related]
11. Identification and functional characterization of nuclear mortalin in human carcinogenesis.
Ryu J; Kaul Z; Yoon AR; Liu Y; Yaguchi T; Na Y; Ahn HM; Gao R; Choi IK; Yun CO; Kaul SC; Wadhwa R
J Biol Chem; 2014 Sep; 289(36):24832-44. PubMed ID: 25012652
[TBL] [Abstract][Full Text] [Related]
12. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
Starenki D; Hong SK; Lloyd RV; Park JI
Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
[TBL] [Abstract][Full Text] [Related]
13. Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4.
Chen CJ; Huang JY; Huang JQ; Deng JY; Shangguan XH; Chen AZ; Chen LT; Wu WH
Cell Cycle; 2023 Apr; 22(8):986-1004. PubMed ID: 36762777
[TBL] [Abstract][Full Text] [Related]
14. METTL3 promotes choriocarcinoma progression by activating the miR-935/GJA1 pathway in an m6A-dependent manner.
Wang W; Shi J; Zheng L
Am J Reprod Immunol; 2023 Nov; 90(5):e13791. PubMed ID: 37881126
[TBL] [Abstract][Full Text] [Related]
15. A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase.
Wu PK; Hong SK; Veeranki S; Karkhanis M; Starenki D; Plaza JA; Park JI
Mol Cell Biol; 2013 Oct; 33(20):4051-67. PubMed ID: 23959801
[TBL] [Abstract][Full Text] [Related]
16. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblasts-derived exosomal METTL3 promotes the proliferation, invasion, stemness and glutaminolysis in non-small cell lung cancer cells by eliciting SLC7A5 m6A modification.
Fan Y; Yu Y
Hum Cell; 2024 Apr; ():. PubMed ID: 38625505
[TBL] [Abstract][Full Text] [Related]
18. Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells.
Starenki D; Sosonkina N; Hong SK; Lloyd RV; Park JI
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027376
[TBL] [Abstract][Full Text] [Related]
19. TP53 status regulates ACSL5-induced expression of mitochondrial mortalin in enterocytes and colorectal adenocarcinomas.
Klaus C; Kaemmerer E; Reinartz A; Schneider U; Plum P; Jeon MK; Hose J; Hartmann F; Schnölzer M; Wagner N; Kopitz J; Gassler N
Cell Tissue Res; 2014 Jul; 357(1):267-78. PubMed ID: 24770931
[TBL] [Abstract][Full Text] [Related]
20. m
Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
